Erasca rises on FDA greenlight for cancer drug trial

Hyterra

17/12/2021 15:32

** Shares of drug developer  ERAS.O  up ~2% at $14.64 
    ** U.S. FDA clears co's application to start human trials
for drug candidate- ERAS-801, specifically designed to have high
central nervous system penetration for the treatment of
recurrent glioblastoma multiforme (GBM)  urn:newsml:reuters.com:*:nGNX1x7gMV 
    ** GBM is an aggressive type of brain or spinal cord cancer
that tends to occur more often in older adults
    ** Co to partner with the Global Coalition for Adaptive
Research (GCAR), an international nonprofit organization, to
determine the feasibility of testing ERAS-801 as part of GCAR's
mid- to late-stage study to identify and advance effective
therapies for GBM 
    ** Involvement in GCAR sponsored study would support "a
clear registrational path in the United States and other key
markets"- ERAS
    ** Co expects to initiate an early-stage clinical study for
ERAS-801 in the first quarter of 2022
    ** Including session moves, stock has fallen 16% since its
July 16 debut

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))